Homepage | Lupus Science & Medicine
Lupus Science & Medicine® is a global, peer reviewed, open access online journal that provides a central point for publication of basic, clinical, translational, and epidemiological studies of all aspects of lupus and related diseases. An official journal of the Lupus Foundation of America (LFA), which is dedicated to advancing the science and medicine of lupus while offering support to ...
Clinical trial outcomes for SLE: what we have and what we need
The paradigm of drug approval in SLE currently relies on successful large phase III randomised controlled trials and a set of primary, secondary and additional end points. Taken together, these outcomes offer a nuanced understanding of the efficacy and safety of the investigational agent. In this review, we thoroughly examine the main outcomes used in SLE trials and highlight unmet ...
About | Lupus Science & Medicine
Lupus Science & Medicine® is a global, peer reviewed, open access online journal that provides a central point for publication of basic, clinical, translational, and epidemiological studies of all aspects of lupus and related diseases. The journal publishes research on lupus from fields including, but not limited to: rheumatology, dermatology, …
Clinical implications of discordance between anti-dsDNA …
Objective Anti-dsDNA antibodies (anti-dsDNA) are a component of all classification schemes in SLE and comprise one of the domains in validated activity indices. Anti-dsDNA is frequently measured commercially by an enzyme immunoassay (EIA) or Crithidia luciliae immunofluorescence test (CLIFT). To address the clinical impact of measuring these antibodies by two different assays, this study ...
Thanoua etΔal Lupus Science Medicine 216e365 doi11136lupus21365 1 Scoring systemic lupus erythematosus (SLE) disease activity with simple, rapid outcome measures Aikaterini Thanou , 1 Judith A James,1,2 Cristina Arriens , 1 Teresa Aberle,1 Eliza Chakravarty,1 Joseph Rawdon,1 Stavros Stavrakis,2 Joan T Merrill,1 Anca Askanase3 To cite: Thanou A, James JA, ...
To treat or not to treat with immunosuppressive therapy: …
Up to 65% of patients with SLE meet the criteria for a psychiatric disorder.1 Especially depression and anxiety are frequently present. Psychiatric disorders are important to recognise as they influence quality of life and treatment outcomes. As a myriad of causes may be responsible for psychiatric manifestations in patients with SLE, clinicians are often confronted with the question: to …
Hydroxychloroquine in the pregnancies of women with lupus: a …
Objective Multiple guidelines recommend continuing hydroxychloroquine (HCQ) for SLE during pregnancy based on observational data. The goal of this individual patient data meta-analysis was to identify the potential benefits and harms of HCQ use within lupus pregnancies. Methods Eligible studies included prospectively collected pregnancies in women …
PO.6.132 A phase 2b study of afimetoran (BMS-986256) in …
Purpose Activation of toll-like receptor (TLR)7/8 by self-RNA induces production of type I interferon and several other proinflammatory cytokines, which may contribute to the pathophysiology of SLE and other related autoimmune diseases. Afimetoran, a potent, selective, oral small-molecule inhibitor of TLR7/8, was developed for potential treatment of autoimmune diseases and has shown robust ...
Systemic lupus erythematosus and neutropaenia: a hallmark of ...
Objective Systemic lupus is a chronic autoimmune disease characterised by its phenotypic heterogeneity. Neutropaenia is a frequent event in SLE occurring in 20%–40% of patients depending on the threshold value of neutrophil count. On a daily basis, the management of neutropaenia in SLE is difficult with several possible causes. Moreover, the infectious consequences of neutropaenia in SLE ...
1201 Flares after SARS-Cov-2 vaccination in patients with systemic ...
Background Vaccination against SARS-CoV-2 is particularly important for patients with systemic lupus erythematosus (SLE), who may be at increased risk of hospitalization for COVID-19. However, the most common reason for vaccine refusal in patients with SLE is fear of SLE disease flare. Additionally, SARS-CoV-2 mRNA vaccines could potentially induce interferon production, associated with ...